Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age

NCT01884740 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT01884740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01884740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2013
Completion date
October 31, 2018
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, brain stem glioma, diffuse intrinsic pontine glioma, fibrillary astrocytoma of brain, glioblastoma multiforme, glioma of brainstem, mixed oligodendroglioma-astrocytoma, pilomyxoid astrocytoma